GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study
This first longitudinal report of GLP-1RA use in youth with T1D and obesity shows clinically meaningful improvements in weight, glycemia, and insulin requirements, supporting the potential role of GLP-1RA as adjunct therapy. Larger prospective studies are needed to guide clinical practice.
Authors
- Lily C. Chao (ORCID: https://orcid.org/0000-0002-6294-0589)
- Fernando Esteban Acosta González (ORCID: https://orcid.org/0009-0005-4035-1336)
- Jaquelin Flores Garcia (ORCID: https://orcid.org/0000-0002-3241-5601)
- Jennifer K. Raymond (ORCID: https://orcid.org/0000-0003-1866-4932)
- Mark W. Reid (ORCID: https://orcid.org/0000-0002-1942-225X)
Institutions
- University of Southern California (US)
- Children's Hospital of Los Angeles (US)
Publication Details
- Journal
- Journal of Pediatric Endocrinology and Metabolism
- Published
- 2025-12-07
- DOI
- https://doi.org/10.1515/jpem-2025-0568
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Novo Nordisk